Can GLP-1 Medications Treat Sleep Apnea? What the Zepbound Trial Data Shows

Direct Answer

Yes, Zepbound (tirzepatide) is the first and only FDA-approved prescription medicine specifically for moderate-to-severe obstructive sleep apnea in adults with obesity. This isn't an off-label use, it's a real, formal FDA indication, backed by the SURMOUNT-OSA Phase 3 trials, published in the New England Journal of Medicine.

The Real Trial Data

SURMOUNT-OSA studied 469 participants across two groups: those not using CPAP/PAP therapy, and those who continued using it during the trial. In the group not using PAP therapy, tirzepatide reduced breathing disruptions (measured by AHI, apnea-hypopnea index) by 50.7%, compared to 3.0% with placebo, and 61% of participants achieved at least a 50% reduction in AHI, versus 19% on placebo. In the PAP-therapy group, results were even stronger: a 58.7% reduction versus 2.5% with placebo, with 72% achieving at least a 50% AHI reduction.

Real, Meaningful Remission Rates

Perhaps the most striking real finding: 42% of participants in the no-PAP group and 50% in the PAP group achieved remission or mild OSA with symptom resolution on tirzepatide, compared to just 16% and 14% respectively on placebo. That's a real, roughly three-fold improvement in the odds of meaningfully resolving OSA symptoms.

Why This Happens, Beyond Just Weight Loss

Weight loss is the primary driver, excess weight is a major, well-established risk factor for OSA, and significant weight reduction directly reduces airway obstruction. But real, published secondary analysis found tirzepatide's OSA-specific improvements were also independently associated with reductions in hypoxic burden and cardiometabolic markers (hsCRP, triglycerides), suggesting a benefit that extends somewhat beyond weight loss alone.

Bottom Line

If you have obesity and moderate-to-severe obstructive sleep apnea, Zepbound is a real, FDA-approved, evidence-based treatment option specifically for this combination, not just a general weight-loss medication that happens to help sleep as a side effect. This is worth discussing directly with your provider or sleep specialist if OSA is part of your health picture.

References

• Eli Lilly and Company: FDA Approves Zepbound as First and Only Prescription Medicine for Moderate-to-Severe OSA
• Malhotra A, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. New England Journal of Medicine
• American Academy of Sleep Medicine: Zepbound Fact Sheet for Sleep Physicians (2026)

Related Resources

• Zepbound Medication Guide
• The SURMOUNT-OSA Trial: Tirzepatide's Sleep Apnea Evidence
• Obstructive Sleep Apnea
• How Do GLP-1 Medications Affect Sleep?

Explore More

Explore the full GLP-1 Tracker knowledge base on DietApp.com

Get Started

Explore the GLP-1 Tracker knowledge base for accurate, sourced information on every GLP-1 medication.

About DietApp.com

DietApp.com combines evidence-based GLP-1 medication education with practical treatment tracking tools. This article is for general informational purposes and is not medical advice.